64951-07-1

基本信息
ETHYL IMIDAZO[1,2-A]PYRIMIDINE-3-CARBOXYLATE
ethyl imidazo[1,2-a]pyrimidine-7-carboxylate
ETHYL IMIDAZO[1,2-A]PYRIMIDINE-3-CARBOXYLATE ISO 9001:2015 REACH
物理化學(xué)性質(zhì)
制備方法

109-12-6

70-23-5
![咪唑并[1,2-A]嘧啶-3-羧酸乙酯](/CAS/GIF/64951-07-1.gif)
64951-07-1
![咪唑[1,2-A]嘧啶-2-甲酸乙酯](/CAS/GIF/64951-06-0.gif)
64951-06-0
以2-氨基嘧啶(5克,52.6毫摩爾)和3-溴丙酮酸乙酯(90%純度,7.35毫升,52.6毫摩爾)為原料,溶于乙醇(80毫升)中,反應(yīng)混合物加熱至75℃反應(yīng)16小時(shí)。反應(yīng)完成后,減壓濃縮反應(yīng)混合物,用二氯甲烷(CH2Cl2)和飽和碳酸氫鈉(NaHCO3)水溶液稀釋。有機(jī)層用飽和NaHCO3水溶液洗滌兩次,水層用CH2Cl2萃取三次。合并有機(jī)層,用無水硫酸鎂(MgSO4)干燥后減壓濃縮。得到的棕色油狀物懸浮于冷的CH2Cl2中,過濾,濾餅用冷CH2Cl2洗滌,得到咪唑并[1,2-a]嘧啶-2-羧酸乙酯(3克,30%收率),為淺黃色油狀物。母液中含有咪唑并[1,2-a]嘧啶-2-羧酸乙酯和咪唑并[1,2-a]嘧啶-3-羧酸乙酯的混合物(6克,60%收率),呈粘稠黑色油狀。該黑色油狀物首先通過硅膠柱色譜法純化,然后從乙酸乙酯(EtOAc)中重結(jié)晶,得到純的咪唑并[1,2-a]嘧啶-3-羧酸乙酯(2克,20%收率)。 對(duì)于2-異構(gòu)體:1H NMR(500MHz,CDCl3)δ8.69(dd,J = 2.2,6.6Hz,1H),8.67(dd,J = 2.2,4.4Hz,1H),8.22(s,1H),7.01(dd,J = 3.9,6.6Hz,1H),4.46(q,J = 7.2Hz,2H),1.43(t,J = 7.2Hz,3H)。13C NMR(500MHz,CDCl3)δ162.8,152.2,147.8,137.7,134.4,115.3,110.0,61.2,14.2。HPLC-MS Phenomenex LUNA C-18 4.6 x 50 mm,0至100%B,4分鐘,1分鐘保持時(shí)間,A = 90%水,10%甲醇,0.1%TFA,B = 10%水,90%甲醇,0.1%TFA,RT = 0.99分鐘,95%均勻度指數(shù)。LCMS:分析。計(jì)算。C9H9N3O2的測(cè)定結(jié)果191.07實(shí)測(cè)值:192.13(M + H)+。 對(duì)于3-異構(gòu)體:HPLC Phenomenex LUNA C-18 4.6 x 50 mm,0至100%B,4分鐘,1分鐘保持時(shí)間,A = 90%水,10%甲醇,0.1%TFA,B = 10%水,90%甲醇,0.1%TFA,RT = 1.39分鐘,100%同質(zhì)性指數(shù)。LCMS:計(jì)算。C9H9N3O2的測(cè)定結(jié)果191.07實(shí)測(cè)值:192.19(M + H)+。
參考文獻(xiàn):
[1] Patent: WO2006/71752, 2006, A1. Location in patent: Page/Page column 83
[2] European Journal of Medicinal Chemistry, 1994, vol. 29, # 4, p. 279 - 286
[3] European Journal of Medicinal Chemistry, 1991, vol. 26, # 1, p. 13 - 18
[4] Journal of Medicinal Chemistry, 2010, vol. 53, # 15, p. 5620 - 5628
[5] Patent: WO2018/11628, 2018, A1. Location in patent: Paragraph 00266